Impact of Anti-Dementia Medication on the Risk of Death and Causes of Death in Alzheimer's Disease.

Clicks: 383
ID: 45777
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #8 of 37 articles by views in Journal of Alzheimer's disease : JAD

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The Finnish population offers many advantages for evaluating the impact of anti-dementia medication on mortality in Alzheimer's disease (AD) due to broad range of individual-level data collected in national health and social care registries and the fact that Finland has one of the highest mortality rates for dementia globally.The aim of this study was to investigate the association of anti-dementia medication with 2-year risk of death and all-cause mortality in patients with AD.This was a retrospective, non-interventional registry study based on individual-level data using Finnish national health and social care registries. An incident cohort of 9,204 AD patients (first AD diagnosis in 2012) was formed from a population of 316,470 individuals ≥74 years of age. The main outcome measure was overall 2-year risk of death. Statistical modelling was used to assess mortality (Kaplan-Meier) and adjusted hazard ratios (HR) (Cox proportional hazard model).Early start of anti-dementia medication (treatment started ≤3 months from AD diagnosis) reduced significantly the risk of all-cause death compared to AD patients who had late medication initiation (defined as treatment started >3 months from AD diagnosis/no medication); HR, 0.51; 95% confidence interval (CI), 0.46-0.57). Dementia was the most common recorded cause of death in both groups.This study places importance on early diagnosis of AD and subsequent early initiation of drug treatment in decreasing 2-year risk of death.
Reference Key
linna2019impactjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Linna, Miika;Vuoti, Sauli;Silander, Katariina;Hörhammer, Iiris;Halminen, Olli;Mikkola, Teija;Koivuranta-Vaara, Päivi;Virta, Lauri J;Koivusalo, Mirkka;Ylisaukko-Oja, Tero;
Journal Journal of Alzheimer's disease : JAD
Year 2019
DOI
10.3233/JAD-190288
URL
Keywords
dementia finland alzheimer’s disease cause of death cholinesterase inhibitors memantine registry study risk of death

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.